Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its recent Type C meeting request from the U.S. Food and Drug Administration (FDA), focused on the ongoing Phase 2 HARMONIC™ trial of LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. In its written responses to Lantern's Type C meeting request, the FDA raised no objections to key.

Business Wire • an hour ago

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates.

Business Wire • May 15, 2026

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor.

Business Wire • May 14, 2026

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor.

Business Wire • May 13, 2026

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026.

Business Wire • May 11, 2026

Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, today unveiled the next phase of its development roadmap for withZeta.ai, the company's multi-agentic A.I. co-scientist platform for oncology research and drug discovery. Future development plans for release in the coming year include three major capability tracks: ZetaSwarm™, an autonomous multi-agent swarm intelligence layer; ZetaOmics™, a real-time computational biology and mul.

Business Wire • May 7, 2026

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript

Seeking Alpha • Apr 30, 2026

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

Seeking Alpha • May 1, 2026

Lantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company advancing precision oncology through its proprietary RADR® AI platform, today announced the expansion of predictBBB.ai into a Large Quantitative Model (LQM) — a real-time quantitative intelligence engine now accessible to any researcher or drug development team, anywhere in the world, through a single browser interface. For the first time, pharmaceutical scientists and medicinal chemists can acce.

Business Wire • Apr 29, 2026

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut.

Business Wire • Apr 24, 2026